Sanofi

Crisp Raises $50M in Series B Extension as CPG Brands Rapidly Adopt a Collaborative Commerce Approach for Sales, Marketing and Supply Chain Management

Retrieved on: 
Thursday, February 22, 2024
Software, Supply Chain Management, Online Retail, Professional Services, Business, Fintech, Data Management, Technology, Retail, Other Professional Services, Finance, Consulting, Cloud, Acquisition, FirstMark Capital, Forecasting, Marketing, Growth, CPG, Kraft Heinz, Sanofi, Blue Cloud Ventures, Hormel Foods, Atlas

TriplePoint Capital LLC provided debt to refinance existing senior debt and to fund both operating activities and continued acquisitions.

Key Points: 
  • TriplePoint Capital LLC provided debt to refinance existing senior debt and to fund both operating activities and continued acquisitions.
  • Crisp previously raised a total of $60M in equity, bringing the total equity raised to $80M.
  • These insights enable brands and retailers to optimize the manufacturing, distribution, merchandising and marketing of CPG products through every retail channel.
  • We solve real problems and help CPG brands strengthen sales, marketing, and their relationships with retailers,” said Are Traasdahl, founder and CEO of Crisp.

ORI Capital Raises $260 Million for Second Life Sciences Fund

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Pharmaceutical, Finance, Oncology, Health, Asset Management, Professional Services, Fintech, Therapy, Cancer, AI, Investment, Synthetic biology, Growth, Vertex, Hope, IPO, Sanofi, RNA, Fund, Patient, Biology, Mortality, DSM-IV codes, Development, DNA, Environment, Pharmaceutical industry

ORI Capital today announced the final close of its second fund, ORI Fund II (the “Fund”), with total commitments of $260 million.

Key Points: 
  • ORI Capital today announced the final close of its second fund, ORI Fund II (the “Fund”), with total commitments of $260 million.
  • Founded in 2015, and led by veteran investor, Simone Song, ORI Capital is well-positioned to identify and nurture the next generation of innovative companies.
  • ORI Capital is a pioneer in adopting a quantamental strategy in biotech venture investment combing data analysis with fundamental research.
  • ORI Healthcare Fund II will actively deploy capital in these new approaches to support truly innovative companies that can bring hope to patients in need globally.

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

Retrieved on: 
Thursday, March 7, 2024
OBE, GSK, Prostate cancer, Parexel, Conference, Human, Sanofi, Patient, MPH, Medicine, Pharmaceutical industry

NEW YORK, March 7, 2024 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 8th annual Patients as Partners® Europe meeting, taking place May 14-15, 2024, at Plaisterers' Hall, in London, England. Patients as Partners® Europe offers an unparalleled opportunity to hear from pharma R&D and patient advocacy on how patient involvement gets done to drive greater efficiencies and inclusivity in clinical research with better outcomes.

Key Points: 
  • Patients as Partners® Europe announces its dates, keynotes and topics for the London meeting which is attended by pharma and biotech R&D, patient advocacy, and technologists to include and empower the patient voice for greater efficiencies in medicine development.
  • NEW YORK, March 7, 2024 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 8th annual Patients as Partners® Europe meeting, taking place May 14-15, 2024, at Plaisterers' Hall, in London, England.
  • Patients as Partners® Europe offers an unparalleled opportunity to hear from pharma R&D and patient advocacy on how patient involvement gets done to drive greater efficiencies and inclusivity in clinical research with better outcomes.
  • "Patients as Partners® Europe presents case examples on how patient involvement in clinical research can accelerate medicine development, how it can improve better access, inclusivity and diversity," said Valerie Bowling, Executive Director
    "Patients as Partners Europe brings advocates and sponsors together in a unique forum focused on improving collaborations that result in meaningful impact for patients," said 2024 co-chair, Victoria DiBiaso, MPH, Global Head, Patient Informed Development & Health Value Translation, Sanofi.

70 companies unite to launch Tent UK, a new coalition of businesses committed to connecting refugees to work

Retrieved on: 
Tuesday, March 5, 2024
The Adecco Group, IHG Hotels & Resorts, Virginity, Compass Group, GSK, Education, Moody's Investors Service, Pret a Manger, Arcadis, Cooperative, Admiral Group, AA, Salesforce, Ageing, IKEA, DLA Piper, Bank, Health, Methodology, Linklaters, EBay, Dow Jones, Microsoft, Partnership, International, Woman, Ben & Jerry's, Thames Water, Cisco, Lineage Logistics, Accenture, Automation, Employment, Starbucks, Bank of America, Research, Bloomberg, Kraft Heinz, Visa, Government, Pret, Data, John Menzies, Foodservice, McDonald's, ISS, Ipsos, BP, Sanofi, HR, Citigroup, Piper, Biogen, Creative industries

LONDON, March 5, 2024 /PRNewswire/ -- The Tent Partnership for Refugees (Tent) – a global network of companies committed to the labour market integration of refugees – is announcing the launch of Tent UK , a coalition of 70 major companies committed to hiring refugees and helping them become job ready.

Key Points: 
  • LONDON, March 5, 2024 /PRNewswire/ -- The Tent Partnership for Refugees (Tent) – a global network of companies committed to the labour market integration of refugees – is announcing the launch of Tent UK , a coalition of 70 major companies committed to hiring refugees and helping them become job ready.
  • Tent is uniquely placed and ready to help companies develop ambitious programmes to include refugees."
  • "Tent is immensely proud to have brought together 70 leading businesses resolved to connect refugees to meaningful employment," said Jen Stobart, UK Director at Tent.
  • Tent UK is Tent's sixth national coalition to launch, adding to existing coalitions in Canada, France, Mexico, Spain and the United States.

Vaniam Group™ Hires Carol Scholz as Executive Vice President of Client Solutions

Retrieved on: 
Monday, March 4, 2024
J&J, AstraZeneca, Oncology, Marketing, GSK, Curio, Growth, Executive Committee, Sanofi, McKesson Corporation, Health, Science

CHICAGO, March 4, 2024 /PRNewswire/ -- Vaniam Group™ today announced the hiring of Carol Scholz as Executive Vice President of Client Solutions. In this role, Ms. Scholz will lead overall client strategy and solutions, while guiding the collaboration and growth of the Client Services department, the Scientific Communications department, and Curio Science™, Vaniam Group's industry leading platform for scientific exchange and insights gathering. She will serve as a member of the Executive Committee and report directly to Vaniam Group's President, Jennifer Buffington Herzog.

Key Points: 
  • CHICAGO, March 4, 2024 /PRNewswire/ -- Vaniam Group™ today announced the hiring of Carol Scholz as Executive Vice President of Client Solutions.
  • In this role, Ms. Scholz will lead overall client strategy and solutions, while guiding the collaboration and growth of the Client Services department, the Scientific Communications department, and Curio Science™ , Vaniam Group's industry leading platform for scientific exchange and insights gathering.
  • She will serve as a member of the Executive Committee and report directly to Vaniam Group's President, Jennifer Buffington Herzog.
  • "Carol brings a passion for delivering strategic solutions and operational excellence, always anchored in the science and centered around the needs of the patient," said Ms. Herzog.

StopAfib.org and Leading Experts Call for Renewed Efforts to Improve Atrial Fibrillation Patient Care During American Heart Month

Retrieved on: 
Wednesday, February 21, 2024
Black History Month, Woman, Education, Research, MD, Quality of life, Cardiology, Ventricular fibrillation, Stroke, American Heart Month, Geography, Arrhythmia, Health, Atrial fibrillation, Sanofi, Patient, Diagnosis, Health equity, Nursing

DALLAS, Feb. 21, 2024 /PRNewswire/ -- StopAfib.org, joined by a task force of experts representing the nation's leading cardiology and cardiothoracic surgery organizations, is calling for renewed efforts to address health disparities and improve care for people living with atrial fibrillation (also known as AF or afib), an irregular and sometimes rapid heartbeat that can cause life-threatening complications, including stroke and heart failure.1

Key Points: 
  • Task force outlines current health disparities and strategies to advance the patient experience across the continuum of care in newly issued call-to-action report.
  • Recognizing the need for more equitable care, StopAfib.org convened the task force to develop a new call-to-action report, "Addressing Health Equity to Improve Atrial Fibrillation Patient Experiences and Outcomes."
  • For patients with AF, timely and proper care is an essential component of long-term health.
  • The report also aims to empower patients to better understand their condition and play a more active role in their care."

Breakthrough 2024 Speaker Lineup Announced - Industry Experts to Discuss the Evolution of Life Sciences Through Technology, Automation, and Artificial Intelligence

Retrieved on: 
Wednesday, February 21, 2024
Name, Merck, AI, Roche, FDA, Food, Johnson & Johnson, Quality, Blueprint, Bristol Myers Squibb, Pharmacovigilance, LLM, Sanofi, Boehringer Ingelheim, Change management, Astellas Pharma, Automation, Philip Morris International

LONDON, Feb. 21, 2024 /PRNewswire/ -- ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, today revealed the speaker line-up for Breakthrough 2024, its annual industry event. Taking place from March 19-20 in London, England, Breakthrough 2024 will facilitate the brightest, forward-looking life sciences industry conversations and serve as the company's showcase where it will announce latest LifeSphere developments.  

Key Points: 
  • Taking place from March 19-20 in London, England, Breakthrough 2024 will facilitate the brightest, forward-looking life sciences industry conversations and serve as the company's showcase where it will announce latest LifeSphere developments.
  • A deep-dive into GenAI's potential role in R&D transformation, as envisioned by a major industry player
    Announcements of the very latest LifeSphere developments.
  • "Breakthrough 2024's content-rich program is designed to inspire and focus industry players in making their next moves as AI continues to evolve and disrupt," said Julie Springer , Chief Marketing Officer at ArisGlobal.
  • Breakthrough2024 will take place March 19-20 at the Leonardo Royal Hotel in London, UK.

Breakthrough 2024 Speaker Lineup Announced - Industry Experts to Discuss the Evolution of Life Sciences Through Technology, Automation, and Artificial Intelligence

Retrieved on: 
Wednesday, February 21, 2024
Name, Merck, AI, Roche, FDA, Food, Johnson & Johnson, Quality, Blueprint, Bristol Myers Squibb, Pharmacovigilance, LLM, Sanofi, Boehringer Ingelheim, Change management, Astellas Pharma, Automation, Philip Morris International

LONDON, Feb. 21, 2024 /PRNewswire/ -- ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, today revealed the speaker line-up for Breakthrough 2024, its annual industry event. Taking place from March 19-20 in London, England, Breakthrough 2024 will facilitate the brightest, forward-looking life sciences industry conversations and serve as the company's showcase where it will announce latest LifeSphere developments.  

Key Points: 
  • Taking place from March 19-20 in London, England, Breakthrough 2024 will facilitate the brightest, forward-looking life sciences industry conversations and serve as the company's showcase where it will announce latest LifeSphere developments.
  • A deep-dive into GenAI's potential role in R&D transformation, as envisioned by a major industry player
    Announcements of the very latest LifeSphere developments.
  • "Breakthrough 2024's content-rich program is designed to inspire and focus industry players in making their next moves as AI continues to evolve and disrupt," said Julie Springer , Chief Marketing Officer at ArisGlobal.
  • Breakthrough2024 will take place March 19-20 at the Leonardo Royal Hotel in London, UK.

SIPCAM AGRO USA EXPANDS INTO CANADA; ADDS NATIONAL ACCOUNT MANAGER

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, AI, Strategic planning, BASF, ADDS, Crop protection, History, Knowledge, Sanofi, Fine chemical

DURHAM, N.C., Feb. 20, 2024 /PRNewswire/ -- Sipcam Agro USA, Inc. is proud to announce its expansion into the Canadian agricultural market, bringing North American formulation capabilities and years of crop and turf protection product experience. Sipcam Agro USA Inc., owned by the Sipcam-Oxon Group, a privately owned Italian company, has been a long-standing participant in the global agricultural industry since 1946.

Key Points: 
  • Sipcam Agro USA Inc., owned by the Sipcam-Oxon Group, a privately owned Italian company, has been a long-standing participant in the global agricultural industry since 1946.
  • SIPCAM AGRO USA EXPANDS INTO CANADA; ADDS NATIONAL ACCOUNT MANAGER
    "This is an exciting time for Sipcam Agro as we increase our customer base in another country and bring quality alternative solutions to the Canadian market," said Brent Marek, CEO/COO of Sipcam Agro and a Canadian native.
  • We are also excited to announce Howie Zander, who is experienced in Canadian Ag, as Sipcam Agro's new National Account Manager in Canada.
  • Sipcam Agro recently acquired the assets of Waynesboro, Mississippi-based Odom Industries including a plant with formulation, packaging and warehousing.

Smart Immune appoints key new members to its Board of Directors

Retrieved on: 
Friday, February 16, 2024
Transfer, Research, Infection, Growth, National Cancer Institute, Immunology, Treatment, Gesellschaft mit beschränkter Haftung, Therapy, Chemical industry in India, Development, Immune system, Roche, Amgen, Dow Chemical Company, Novartis, Farmitalia, Dow, Lazard, XPath, Medical research, Spark Therapeutics, ADC, Patient, Sanofi

Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.

Key Points: 
  • Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.
  • Karine Rossignol, CEO and Co-founder of Smart Immune, said: “We are delighted and proud to welcome such distinguished experts to the Board, led by Markus Goebel as our new Chairman.
  • We are grateful to our outgoing Chairman for his 5-year commitment and support to Smart Immune.”
    Markus Goebel, CEO and Founder of M&G Advisors and Chairman of Smart Immune’s Board of Directors, said: “I am thrilled to join and lead the Board of Smart Immune.
  • He is on the Boards of Halozyme, ADC Therapeutics and Aprea Therapeutics and now an Observer on the Board of Directors at Smart Immune.